{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:45:00Z","timestamp":1764078300851},"reference-count":9,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2002,11,23]],"date-time":"2002-11-23T00:00:00Z","timestamp":1038009600000},"content-version":"vor","delay-in-days":267,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Safety and efficacy of KOGENATE<jats:sup>\u00ae<\/jats:sup> Bayer (Kogenate<jats:sup>\u00ae<\/jats:sup> FS), a second\u2010generation full\u2010length recombinant factor VIII formulated with sucrose as stabilizer and produced without the addition of human albumin during purification and the final formulation, was assessed in a prospective, international clinical trial including 31 previously untreated patients (PUPs) and minimally treated patients (MTPs) with severe haemophilia A in home therapy and surgery. Factor VIII inhibitor development was monitored and mutation type profiles were analysed. As of 30 June\u20032000, the patients received a total of 2.729 infusions (mean 88; range 6\u2013274) for bleeding episodes, surgery or prophylactic treatment. No unexpected drug\u2010related adverse events were observed. Four patients developed an inhibitor after 3\u201312 exposure days (EDs). One patient successfully underwent immune tolerance treatment; inhibitors in two patients disappeared spontaneously with on\u2010demand treatment, while the inhibitor titre remains low in one patient. Twenty\u2010nine patients (93%) with more than 20 EDs can be regarded as at low risk for inhibitor development. In conclusion, KOGENATE<jats:sup>\u00ae<\/jats:sup> Bayer is efficacious and well\u2010tolerated for treatment of children with severe haemophilia A. The incidence of inhibitor formation is not different to that observed with other recombinant or plasma\u2010derived products.<\/jats:p>","DOI":"10.1046\/j.1351-8216.2001.00133.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:08:54Z","timestamp":1047406134000},"page":"19-22","source":"Crossref","is-referenced-by-count":31,"title":["Safety and efficacy of KOGENATE<sup>\u00ae<\/sup> Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs)"],"prefix":"10.1111","volume":"8","author":[{"given":"P. L. F.","family":"Giangrande","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"BAYER STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,11,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613925"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00432.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/00313029500169542"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649954"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70419-0"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199811000-00008"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90874-3"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00191.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00300.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1351-8216.2001.00133.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1351-8216.2001.00133.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:14:35Z","timestamp":1695730475000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1351-8216.2001.00133.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":9,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1046\/j.1351-8216.2001.00133.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1351-8216.2001.00133.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"type":"print","value":"1351-8216"},{"type":"electronic","value":"1365-2516"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}